Compare Barrick Gold Corp (B) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barrick Gold Corp vs Neurocrine Biosciences Inc — how do they compare? Barrick Gold Corp trades at $35.84 (market cap $60.50B), while Neurocrine Biosciences Inc trades at $175 (market cap $17.30B). The key difference: Barrick Gold Corp is far larger — about 3.5× Neurocrine Biosciences Inc's market cap, and Barrick Gold Corp pays a 1.92% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| B | NBIX | |
|---|---|---|
Market Cap | $60.50B | $17.30B |
Sector | Basic Materials | Health |
52-Week High | $52.97 | $180.55 |
52-Week Low | $20.73 | $123.10 |
Enterprise Value | $58.09B | $16.39B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barrick Mining (B) trades at $35.94, down 2.02% today, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.07, net income margin of 32.14%, and three consecutive quarterly EPS beats. Recent cash flow trends improved significantly, with 2025 net cash flow turning positive at $2.63 billion. The company announced a $0.18 dividend payable in June 2026.
The outlook remains positive given low valuation multiples, robust profitability, and analyst consensus of $52.67 price target. Key risks include gold price volatility and execution of growth projects. With 68% analyst buy ratings and no sell recommendations, Wall Street sentiment supports long-term upside potential despite near-term technical weakness.
Neurocrine Biosciences (NBIX) trades at $174.10, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and support at $173. The company demonstrates robust fundamentals with Q1 2026 revenue growth of 44% year-over-year to $811 million and consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected. Recent pipeline advancements include Phase 2 studies for crinecerfont and positive VYKAT XR data presented at ENDO 2026.
NBIX presents compelling growth prospects with analyst consensus price target of $195.75 (12% upside) and 86% buy ratings. Key opportunities include blockbuster drug performance and strategic acquisitions, while risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's current valuation at 26.5x P/E reflects growth expectations but requires continued execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
